Opinion|Videos|May 2, 2025
Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
Panelists discuss how recurrent urinary tract infections (UTIs) treated with older antibiotics generate 2 to 3 times higher total costs than initial savings, warranting cost-effectiveness analyses in treatment decisions, whereas payers create barriers to newer therapies through restrictive authorizations, high co-pays, step therapy mandates, and limited formulary inclusion that providers can navigate via detailed documentation, pharmacy benefit manager engagement, patient assistance programs, and advocacy for evidence-based coverage policies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- To what extent does the economic burden of recurrence in patients treated with older, more affordable drugs offset the initial cost savings, and how should this affect treatment decisions?
- What payer-related barriers might arise for these emerging treatments for patients who have experienced treatment failure with traditional therapies?
- How can health care providers advocate for their patients in these situations?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
5